Publications by authors named "Concepcion Boque"

Claim this Profile
C
Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations.
Concepción Boqué, Silvia Sánchez-Ramón, Raúl Córdoba, Carol Moreno, Elena Cabezudo

J Clin Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque, Blanca Xicoy, Pilar Giraldo

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients.
Natalia Estrada, Lurdes Zamora, Francisca Ferrer-Marín, Laura Palomo, Olga García

J Clin Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients.
Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales

Hemasphere· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.
Maria Condom, Alberto Mussetti, Clara Maluquer, Rocío Parody, Eva González-Barca

Cancer Rep (Hoboken)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Sílvia Marcé, Blanca Xicoy, Olga García, Marta Cabezón, Natalia Estrada

J Clin Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Valentín Garcia-Gutiérrez, Alejandro Luna, Juan M Alonso-Dominguez, Natalia Estrada, Concepcion Boque

Blood Cancer J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.
Concepción Boqué, María Reyes Abad, María José Agustín, Manuel García-Goñi, Carolina Moreno

J Geriatr Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms.
Pamela Acha, Marisol Xandri, Francisco Fuster-Tormo, Laura Palomo, Blanca Xicoy, Concepcion Boque

Am J Hematol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
Valentín García-Gutiérrez, Dragana Milojkovic, Juan Carlos Hernandez-Boluda, Simone Claudiani, María Luisa Martin Mateos, Concepcion Boque

Ann Hematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Juan Carlos Hernández-Boluda, Arturo Pereira, Irene Pastor-Galán, Alberto Alvarez-Larrán, Alisa Savchuk

Blood Cancer J· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alberto Alvarez-Larrán, Manuel Pérez-Encinas, Francisca Ferrer-Marín, Juan Carlos Hernández-Boluda, María José Ramírez

Haematologica· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly variable mutational profile of ASXL1 in myelofibrosis.
Marc Sorigué, Josep-Maria Ribera, Olga García, Marta Cabezón, Patricia Vélez

Eur J Haematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
Lurdes Zamora, Blanca Xicoy, Marta Cabezón, Cristalina Fernandez, Silvia Marcé

Leuk Lymphoma· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Jorge E Cortes, Giuseppe Saglio, Hagop M Kantarjian, Michele Baccarani, Jiří Mayer

J Clin Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Valentín García-Gutiérrez, Alejandra Martinez-Trillos, Jose Luis Lopez Lorenzo, Guiomar Bautista, Maria Luisa Martin Mateos

Am J Hematol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.
Emmanuel Gimenez, Carles Besses, Concepcion Boque, Patricia Velez, Ana Kerguelen

J Med Econ· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Juan-Carlos Hernández-Boluda, Arturo Pereira, Montse Gómez, Concepción Boqué, Francisca Ferrer-Marín

Haematologica· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Elias Jabbour, Hagop M Kantarjian, Giuseppe Saglio, Juan Luis Steegmann, Neil P Shah

Blood· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Juan-Carlos Hernández-Boluda, Arturo Pereira, Francisco Cervantes, Alberto Alvarez-Larrán, María Collado

Blood· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study.
Fermin M Sánchez-Guijo, Soledad Durán, Josefina Galende, Concepción Boqué, José B Nieto

Leuk Res· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop Kantarjian, Neil P Shah, Andreas Hochhaus, Jorge Cortes, Sandip Shah

N Engl J Med· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Blanca Espinet, Ana Carla Oliveira, Concepción Boqué, Alicia Domingo, Esther Alonso

Haematologica· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.
Jose Roman-Gomez, Juan A Castillejo, Antonio Jimenez, Francisco Cervantes, Concepcion Boque

J Clin Oncol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis